Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, CXP

Autolus Therapeutics Enters Lease with Alexandria Real Estate Equities, Inc. for Future Commercial-Scale Manufacturing Site and U.S. Headquarters


LONDON, Jan. 14, 2019 /PRNewswire/ -- Autolus Therapeutics plc (NASDAQ: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has signed a long-term, full-building lease with Alexandria Real Estate Equities, Inc. (NYSE: ARE) for the construction and development of an 85,000 square foot build-to-suit facility to be located in the Shady Grove Life Sciences Center in Rockville, Maryland. The new facility will house offices for Autolus' U.S.-based research and development, commercial and corporate functions and serve as its first full commercial-scale manufacturing center, with a planned capacity to produce 5,000 T cell therapies annually. In addition, Autolus has established a temporary U.S. headquarters in Rockville until the new facility is ready for occupancy, which is currently expected to occur in 2021.

"This facility in the United States will be purpose-built to deliver on our commitment to provide advanced T cell therapies to patients based on a manufacturing process designed to be scalable and economical," said Dr. Christian Itin, chairman and chief executive officer of Autolus.

In addition to the future full commercial-scale manufacturing facility in the United States, Autolus is also initiating build-out of a manufacturing facility in Enfield, U.K. that will open in 2020 and supply global commercial viral vector as well as commercial T cell therapy products.

About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.  For more information please visit www.autolus.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the company's product candidates and research programs. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in the company's Annual Report on Form 20-F filed on November 23, 2018 as well as discussions of potential risks, uncertainties, and other important factors in the company's future filings with the Securities and Exchange Commission from time to time. All information in this press release is as of the date of the release, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Investor contact:
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com

Media contact:
Silvia Taylor
Vice President, Corporate Affairs and Communications, Autolus
+1-240-801-3850
s.taylor@autolus.com

Julia Wilson
JW Communications
+44 (0) 7818 430877
juliawilsonuk@gmail.com

SOURCE Autolus Therapeutics plc


These press releases may also interest you

at 12:30
Kellogg's* Special K* is taking a stand on women's health and introducing Escape the Nonsense, Canada's first interactive pop-up of its kind that invites Canadian women to ditch the nonsense on their health journey and own every bite of life....

at 12:27
Pankey's year-long celebration includes special events and regional meetings and culminates in the Pankey Annual Meeting on Sept. 12-14, 2019 at the Ritz-Carlton Key Biscayne, Florida. Dentists can register for the meeting by visiting:...

at 12:20
PrimeVax Immuno-Oncology, Inc. announced today that the company has just signed an exclusive, worldwide license with the US Army Medical Materials Development Activity, Ft. Detrick, MD, USAMMDA, authorizing PrimeVax to use dengue virus-1 #45AZ5...

at 12:06
Revolution Enterprises ("Revolution" or "Company"), a national leader in the cannabis industry, is pleased to announce the appointment of Mr. Tony Hunter and Mr. Jim Oliff to its Board of Directors. Mr. Hunter, former CEO of Tribune Publishing and...

at 12:04
Henry Schein, Inc. announced today that it ranks first in its category on the FORTUNE® "World's Most Admired Companies" list for 2019. This recognition by FORTUNE marks the 18th consecutive year that Henry Schein has been named to the overall list....

at 12:00
OrthogenRx, Inc., a medical device company focused on the development and commercialization of treatments for musculoskeletal conditions including osteoarthritis (OA) has announced the launch of TriVisc® (sodium hyaluronate) for the treatment of...



News published on 14 january 2019 at 07:55 and distributed by: